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volves an initial hyperplastic growth period that switches to aG1 kinases and transforming growth factor-b signaling are asso-
hypertrophic growth period within a couple of days. The pat-ciated with a growth pattern switch in diabetes-induced renal
tern of G1 kinase activity associated with the growth patterngrowth.
switch demonstrates that the hypertrophy is mediated by a cellBackground. Diabetes mellitus-induced nephromegaly is
cycle-dependent mechanism. Regulation of TGF-b receptorthought to involve both hyperplastic and hypertrophic proxi-
expression and signaling activity through the Smad proteinmal tubule cell growth. The temporal relationship between
cascade possibly plays a role in the growth pattern switch.these growth patterns and the mechanisms that mediate them
are unknown.
Methods. Renal growth was assayed in isolated renal proxi-
mal tubules harvested from diabetic rats. Diabetes mellitus was
The progressive loss of renal function in diabetic pa-induced by streptozotocin.
tients correlates with the development of enlarged kid-Results. Following the induction of a diabetic state, there
was a progressive increase in the kidney:body weight ratio. This neys and occurs in about 40% of type I and 20% of type
was associated with an increase in 5-bromo-2-deoxyuridine II diabetic patients [1]. In human diabetes mellitus and
incorporation (marker for hyperplastic cell growth) at day 2, diabetic rodent models, this nephromegaly is thought towhich returned to baselines levels by day 4, and an increase in
involve both hyperplasia (an increase in cell number)the protein:DNA ratio (marker for hypertrophic cell growth),
and hypertrophy (an increase in cell size) of the proximalwhich was clearly evident by day 10. Thus, diabetes-induced
proximal tubule growth involved an initial hyperplastic, fol- tubule [2–7].
lowed by a hypertrophic, growth period. During the hyperplas- Using in vitro cell culture models of renal epithelial
tic growth period, both cdk4/cyclin D (cyclin D) and cdk2/ cell growth, we have characterized cell cycle-dependentcyclin E (cyclin E) kinase activities were increased. The switch
and -independent mechanisms that can mediate the de-between the growth periods was associated with continued
velopment of hypertrophy [8–13]. The cell cycle-depen-activation of cyclin D, but inhibition of cyclin E kinase. The
reduction in cyclin E kinase activity correlated with a reduction dent mechanism requires the combined effects of mito-
in cdk2/cyclin E complex abundance and an increased abun- gen-induced movement of cells into the G1 phase of thedance of cyclin kinase inhibitors in cdk2/cyclin E complexes
cell cycle, followed by arrest of cell cycle progressionthat did form. Also associated with the switch in growth pat-
at the G1/S interface. This hypertrophy mechanism isterns was a change in transforming growth factor-b (TGF-b)
receptor expression. During the hyperplastic growth period, associated with regulation of both of the G1 kinases,
TGF-b receptor II expression was decreased, while during the cdk4/cyclin D (cyclin D), and cdk2/cyclin E (cyclin E).
hypertrophic growth period, there was both a return of receptor Cyclin D and E kinases function synergistically to pro-
II expression to baseline levels and increased expression of
gress the cell through the G1 phase of the cell cyclereceptor I. Consistent with an increase in TGF-b signaling
[14–16]. Cyclin D kinase is activated early in G1 at theduring hypertrophy, there was an increase in Smad 2/3 protein
expression and an increase in the abundance of Smad 2/4 com- same time that the cells are undergoing an increase in
plexes. physical size. Cyclin D kinase phosphorylates some of
Conclusions. Diabetes-induced proximal tubule growth in- the sites on the retinoblastoma protein (pRB), rendering
the protein active in this hypophosphorylated state.
When active, pRB binds the transcription factor E2FKey words: renal hypertrophy, cell cycle-dependent hypertrophy,
Smad proteins, proximal renal tubule, hyperplasia, nephromegaly. and prevents transcription of genes required for DNA
synthesis during the S phase. In late G1 phase, cyclin EReceived for publication August 23, 1999
kinase is activated. This kinase phosphorylates addi-and in revised form December 28, 1999
Accepted for publication February 4, 2000 tional sites on pRB, rendering the protein inactive, and
thus unable to bind E2F. In its unbound state, E2F initi-Ó 2000 by the International Society of Nephrology
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ates transcription of S phase-required genes, permitting METHODS
the cell to begin DNA synthesis. Streptozotocin (STZ)-induced diabetes mellitus
Our current working model for cell cycle-dependent Male Sprague-Dawley rats weighing 200 to 300 g were
hypertrophy is that cyclin D kinase mediates the physical used. All animals had free access to water and standard
growth of the cell that is necessary for both hyperplastic rat chow throughout the study. Rats were divided into
and hypertrophic growth. Cyclin E kinase determines three groups, and all animals were otherwise treated
whether the growth pattern will be one of hyperplasia equivalently. Two groups received a single tail vein injec-
(cyclin E activation, progression into S phase, and com- tion of STZ (Sigma, St. Louis, MO, USA) dissolved in
pletion of the remaining phases of the cell cycle) or hyper- 0.1 mol/L sodium citrate (pH 4.5) at a dose of 30 mg/kg
trophy (inhibition or insufficient activation of cyclin E body weight. The diabetic group (DM) did not receive
kinase to permit progression into S phase, and therefore, replacement insulin therapy. In this group, only those
arrest of cell cycle progression) [10–12]. When cyclin D rats with a blood glucose concentration (measured mid-
kinase is activated and cyclin E kinase inhibited, the cells morning in all animals) over 300 mg/dL 24 hours after
remain under the growth-stimulatory effects of cyclin D the STZ dose and at the time of sacrifice and with nega-
kinase, but are prevented from duplicating their DNA tive urine ketones were included in the studies. The
and dividing because cyclin E kinase is not sufficiently insulin-replacement diabetic group received the same
activated to permit progression into S phase. The result STZ dose described above plus 4 U/day of Humulin U
is a physically enlarged or hypertrophied cell. Ultralente insulin. Only those rats with a normal blood
Diabetes mellitus is associated with increased growth glucose everyday (measured midmorning in all animals)
factor and transforming growth factor-b (TGF-b) ex- and at the time of sacrifice were included in the studies.
The control group received a single tail vein injectionpression [17–20]. The growth factors could provide the
of the 0.1 mol/L sodium citrate vehicle. Animals werestimulus for cells to enter into the G1 phase, while in-
sacrificed 2, 4, 5, 7, or 10 days after the tail vein injection.creased TGF-b expression could mediate the arrest of
cell cycle progression because of its antiproliferative ef-
DNA synthesisfects. Thus, it is possible that the cell cycle-dependent
To examine rates of DNA synthesis, 5-bromo-2-deoxy-hypertrophy mechanism plays a role in diabetes-induced
uridine (BrdU) incorporation was measured. Animalsrenal growth.
received a single intraperitoneal injection of 100 mgTo determine whether diabetes-induced renal growth
BrdU/g body weight two hours prior to sacrifice. Whenis associated with regulation of the G1 kinases, kinase
the kidneys were harvested (discussed later in this arti-activity and proximal tubule growth patterns were exam-
cle), a central transverse section of kidney was placedined in tubules isolated from diabetic rats. The results
in 10% formaldehyde in phosphate-buffered salineshow that the initial proximal tubule growth response is
(PBS) 3 24 hours and then in PBS until paraffin embed-hyperplasia, during which both cyclin D and E kinases
ded, and a 3 to 4 mm slice was mounted on a lysine-are activated. This growth period is followed by a hyper-
coated glass slide. BrdU incorporation into DNA wastrophic growth period. Cyclin D kinase remains activated
measured by immunohistochemistry using anti-BrdU an-during the hypertrophic growth period, while cyclin E
tibodies as per the kit protocol (Oncogene Research
kinase is inhibited. The pattern of kinase regulation asso-
Products, Cambridge, MA, USA). Counterstaining was
ciated with the development of hypertrophy is consistent done with hematoxylin. Data are reported as the average
with involvement of a cell cycle-dependent mechanism. number of BrdU-positive cells in the outer cortex in five
Both a decrease in cdk2/cyclin E complex abundance and high-powered fields.
an increase in the abundance of cyclin kinase inhibitors
(CKIs) associated with cdk2/cyclin E complexes that do Isolation of intact proximal tubules
form are associated with the time point of cyclin E kinase Rats were anesthetized, and both kidneys were re-
inhibition, providing two mechanisms that might mediate moved through an abdominal incision and immediately
the decrease in kinase activity. The switch between the placed in ice-cold PBS. The superficial cortex was care-
hyperplastic and hypertrophic growth periods is also as- fully dissected, sliced with a Stadie-Riggs tissue slicer,
sociated with regulation of both TGF-b type I and II and put into ice-cold PBS containing protease inhibitors.
receptors (TGF-b RI and RII, respectively), Smad 2/3 The cortical slices were washed three times with Prep-
protein abundance, and the abundance of Smad 2/4 com- Media (50:50 mixture of low-glucose Dulbecco’s modi-
plexes, suggesting that TGF-b plays a role in switching fied Eagle’s medium:Ham’s F12; GIBCO BRL, Gaith-
the growth pattern from hyperplasia to hypertrophy, ersburg, MD, USA), suspended in 10 mL of 95% O2/5%
probably by arresting cell cycle progression in the late CO2 pre-equilibrated Prep-Media containing 1.9 mg/mL
collagenase B (Boehringer Mannheim, Germany), andG1 phase.
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incubated in a 378C shaking water bath for 8 to 10 min- 10 minutes at 48C. The supernatant was discarded, and
the beads washed four times with 1 mL lysis buffer,utes. After collagenase digestion, 10 mL of ice-cold Prep-
Media were added to the tissue suspension to stop the followed by three additional washings with 1 mL kinase
reaction buffer that did not contain either cold or hotcollagenase digestion reaction. The tissue suspension was
then kept on ice continuously. adenosine 59-triphosphate (ATP) or kinase substrate
(discussed later in this article). Following the last wash,Proximal tubules were collected using a sieving tech-
nique [21, 22]. The digested tissue suspension was first the bead pellet was resuspended in 30 mL of kinase
reaction buffer containing ATP and kinase substrate [50passed through an 80 mesh size minisieve (80 openings/
linear inch; Fisher, Pittsburgh, PA, USA). The flow mmol/L Tris-HCl, pH 7.4, 10 mmol/L MgCl2, 1 mmol/L
dithiothreitol (DTT), 70 mmol/L NaCl, 0.1 mmol/L ATP,through, which contained the proximal tubules, was then
passed through a 170 mesh size (170 openings/linear 0.2 mg/mL histone H1, and 0.2 mCi/mL [g-32P]ATP (6000
Ci/mmol)]. The reaction was carried out by gently shak-inch). The proximal tubules, which remained on the sieve
filter this time, were collected and suspended in 20 mL ing the sample in a 308C water bath for 30 minutes. The
kinase reaction was stopped by the addition of 7.5 mLPrep-Media, and the tubules pelleted by gravity sedimen-
tation for five minutes. The sedimentation process was Laemmli sample buffer. The samples were then boiled for
three minutes and size separated by sodium dodecyl sul-repeated twice after resuspending the tubules in ice-cold
PBS containing protease inhibitors to insure removal of fate-polyacrylamide gel electrophoresis (SDS-PAGE) on
a 13% gel. The gel was stained with Commassie blue stainany remaining cellular debris. The final sedimented pel-
let was kept on ice until used. to confirm equal amounts of kinase substrate in each
sample and destained and dried. Phosphorylated sub-
Protein:DNA ratio strate was visualized by autoradiography and was quanti-
tated by densitometry.Isolated proximal tubules were suspended in 0.5 mL
hypotonic lysis buffer (50 mmol/L NaH2PO4, pH 7.4) Cdk4/cyclin D kinase activity. Cyclin D kinase activity
was measured using the same protocol described pre-containing protease inhibitors and sonicated four times
for five seconds each while on ice. Half of the resulting viously in this article with the following exceptions, as
we previously reported [10]. The lysis buffer containedsuspension was diluted with the same volume (0.25 mL)
of hypotonic lysis buffer containing 2 mmol/L ethylene- 150 mmol/L NaCl, 1 mmol/L EDTA, 2.5 mmol/L ethyl-
eneglycol tetraacetic acid (EGTA), 10% glycerol, 0.1%diaminetetraacetic acid (EDTA) and was used to mea-
sure DNA content. The other half of the suspension was Tween 20, and 1 mmol/L DTT plus protease inhibitors.
The immunoprecipitating antibody was a rabbit anti-used to measure protein content. The protein and DNA
concentrations of the proximal tubule lysate were mea- cdk4 antibody (Santa Cruz Biotechnology), and the cdk4
kinase reaction buffer contained 10 mmol/L MgCl2, 50sured by the Lowry method and by using the fluorescent
compound Hoechst H33258, respectively, as we pre- mmol/L HEPES, pH 7.5, 2.5 mmol/L EGTA, 10 mmol/L
b-glycerophosphate, 0.1 mmol/L Na3VO4, 1 mmol/Lviously reported [9, 23, 24].
NaF, 1 mmol/L DTT, 20 mmol/L ATP, 0.2 mCi/mL [g-
G1 kinase activity 32P] ATP (6000 Ci/mmol), and 0.01 mg/mL GST-pRB
[pRB amino acids 769 to 921 fused to glutathioneCdk2/cyclin E kinase activity. Cyclin E kinase activity
was measured using a protocol similar to that which S-transferase (GST); Santa Cruz Biotechnology].
we have previously published [10]. Briefly, the purified
Immunoprecipitation and Western blottingproximal tubules were resuspended in 600 to 800 mL
lysis buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH Protein abundance was measured by Western blotting
as previously reported [9, 10]. In studies examining the7.4, depending on yield) containing protease inhibitors,
sonicated four times for five seconds each on ice, and abundance of proteins that coprecipitate with cyclin E
or Smad 4, the immunoprecipitation protocol was ascentrifuged at 4000 r.p.m. for four minutes at 48C. The
supernatant was used to measure the protein concentra- described previously in this article, except that 1500 mg
of proximal tubule lysate protein were incubated with 5tion of the resulting proximal tubule lysate, using a Bio-
Rad protein assay kit (Bio-Rad Laboratories, Hercules, mg rabbit anticyclin E or Smad 4 antibody, respectively.
Following incubation with protein G agarose, the immu-CA, USA). Cyclin E was immunoprecipitated by adding
1 mg rabbit anticyclin E antibody (Santa Cruz Biotech- noprecipitated proteins were boiled in Laemmeli sample
buffer, electrophoresized on a 13% SDS-PAGE gelnology, Santa Cruz, CA, USA) to 500 mg of tubule pro-
tein. The immunoprecipitation reaction was carried out electrophoresis gel, transferred to a nitrocellulose mem-
brane, and probed with anti-cdk2, -Smad 2 or 3, -p21, -p27,overnight at 48C with gentle rotation. The next day, 100
mL protein-G agarose beads were added, and the sample or -p57 antibodies as appropriate (all antibodies were
obtained from Santa Cruz Biotechnology). Bands wereincubated at 48C with gentle rotation for one hour. The
beads were collected by centrifugation at 4000 r.p.m. for detected using enhanced chemiluminescence (ECL), and
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Fig. 2. 5-Bromo-2-deoxyuridine (BrdU) incorporation. Symbols are:
(d) control; (e) diabetic animals. Cortical BrdU incorporation was
measured and reported as described in the Methods section (N 5 5 to
10 per group per time point). *P , 0.05 vs. control (vehicle-treated
animals).
Fig. 1. Diabetes mellitus-induced renal growth. Animals were made
diabetic and kidneys harvested as described in the Methods section.
(A) Total kidney weight, plotted as a percentage of control (vehicle)-
treated animals. (B) The ratio of kidney:body weight in (d) control
and (e) diabetic animals [N 5 14 to 16 (day 2), 7 to 9 (day 4), 18 to
21 (day 5), 5 to 10 (day 7), and 7 to 8 (day 10)]. *P , 0.05 vs. control.
Fig. 3. Protein:DNA ratio. The protein:DNA content ratio was mea-
sured on isolated proximal tubules as described in the Methods section
(N 5 2 to 7 per group per time point). Symbols are: (j) control; ( )
diabetic animals. *P , 0.05 vs. control (vehicle-treated animals); #P ,the abundance was quantitated by scanning densitom-
0.05 vs. increase at day 2.etry.
For studies examining TGF-b receptor I or II protein
abundance, Western blotting of proximal tubule lysate
was done using anti-TGF-b receptor I (RI) or II (RII) been shown by many investigators, within days after the
specific antibodies, which were obtained from Santa Cruz induction of diabetes mellitus, the kidney enlarges. The
Biotechnology. first study, done to determine the type of growth respon-
sible for this kidney enlargement, was to examine BrdU
Statistics incorporation during the growth period. As shown in
Statistical significance was determined by the appro- Figure 2, there was a small but significant increase in
priate t-test. Differences between means were consid- cortical BrdU incorporation at day 2, which returned to
ered significant if P , 0.05. baseline levels by day 4 and remained at baseline levels
through day 10. These data suggest that following the
induction of a diabetic state, there is a short period ofRESULTS
renal cortical hyperplasia, followed by a prolonged non-
Renal growth following the induction of DM hyperplastic growth period.
Figure 1 shows the effect of diabetes mellitus on total To determine whether any of the renal growth is due to
proximal tubule hypertrophy, the protein:DNA contentkidney weight and the kidney:body weight ratio. As has
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Fig. 4. Comparison of plasma glucose concentrations and growth parameters in control rats (j), diabetic rats treated with insulin ( ), and
untreated diabetic rats ( ). All assays were performed as described in the Methods section. For control (control), treated diabetic (DM 1 insulin
Rx), and untreated diabetic (DM) mice, the number of animals/group was as follows, respectively: plasma (glucose) and kidney:body weight ratio:
22, 6, 14 (2 days) and 14, 6, 7 (10 days); BrdU incorporation: 13, 6, 5 (2 days) and 12, 6, and 6 (10 days); and protein:DNA ratio: 13, 6, 5 (2 days)
and 9, 6, 7 (10 days). *P , 0.05 for DM vs. control and DM 1 insulin; #P , 0.05 for DM 1 insulin vs. control.
ratio of isolated proximal tubules was measured. As shown in Figure 4B, almost the entire increase in the
kidney:body weight ratio was blocked by insulin therapyshown in Figure 3, there was a small increase in the
protein:DNA ratio at day 2, which was clearly evident at both time points. Similarly, insulin therapy prevented
almost the entire increase in BrdU incorporation (mark-by day 10. The magnitude of the increase at day 10
(39.2%) was significantly different than at day 2 (13.9%; er for hyperplasic growth; Fig. 4C) and the increase in
the protein:DNA ratio (marker for hypertrophic growth;Fig. 3). These data demonstrate that the majority of the
hypertrophic growth occurs after the initial hyperplastic Fig. 4D). Thus, neither the diabetes-induced hyperplasia
nor hypertrophy is a side effect of STZ.growth period. The small increase in the protein:DNA
ratio at day 2 likely represents biological variability be-
G1 kinase activity during diabetes-induced renaltween tubules in the timing of the initiation of the hyper-
hyperplasia and hypertrophytrophic growth response.
To confirm that the growth effect was due to the dia- The next series of experiments was done to define
the mechanism associated with both the hyperplasia andbetic state and not a side effect of STZ, studies were
done in diabetic rats treated with insulin to maintain a hypertrophy and the cause of the switch between the
two growth patterns. Both G1 kinase activities, cdk4/normal plasma glucose level. As shown in Figure 4A,
insulin therapy corrected the hyperglycemic state. Three cyclin D (cyclin D) and cdk2/cyclin E (cyclin E), were
measured on isolated proximal tubules. Figure 5A showsgrowth parameters were measured (Fig. 4 B–D). As
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E kinase was inhibited fits our model of cell cycle-depen-
dent hypertrophy and is consistent with the lack of BrdU
incorporation during the hypertrophic growth period
[9–12]. In the in vitro studies that characterized this type
of hypertrophy, it was found that the inhibition of cyclin
E kinase activity associated with the conversion from a
hyperplastic to hypertrophic growth period was due to
both a decrease in the abundance of cdk2/cyclin E kinase
complexes and an increase in the association of CKIs
with complexes that did form [10]. To determine whether
these mechanisms were involved in the inhibition of
cyclin E kinase activity at day 5, similar studies were
done.
Figure 6 (left panel) shows typical blots, while the
right panel is a summary of the data examining the abun-
dance of cdk2/cyclin E complexes. As shown at day 2,
there was a large, significant increase in the amount of
cdk2 that coprecipitated with cyclin E, demonstrating
an increase in the abundance of cdk2/cyclin E com-
plexes. This observation was consistent with a hyperplas-
tic growth response. However, by day 5, the abundance
of cdk2/cyclin E complexes was reduced, and by day 10,
it was almost back to baseline levels. Although complex
abundance was still significantly increased compared
with control animals at days 5 and 10, it was significantly
smaller than at day 2 (Fig. 6). A large reduction in com-
plex abundance provided a mechanism by which cyclin
E kinase activity may be reduced. However, since the
mechanism by which complex abundance was reduced
was not able to fully inhibit the complex formation, it is
likely that another mechanism contributes to the inhibi-
tion of kinase activity.
To determine whether the inhibition of cyclin E kinase
activity also involved preventing activation of formed
cdk2/cyclin E complexes, studies were done to examine
Fig. 5. Regulation of cyclin D and E kinase activities during diabetes the abundance of CKIs associated with cdk2/cyclin E
mellitus-induced renal growth. Kinase activities were measured on
complexes. Figure 7 shows the ratio of CKI:cdk2 in cyclinisolated proximal tubules as described in the Methods section and
reported as a percentage of control (vehicle-treated animals; N 5 4 to E immunoprecipitates for the three CKIs that associate
9 per kinase per group per time point). (A) Representative blots. (B) with cdk2/cyclin E complexes. As shown in the left set
Summary of all experiments. Symbols are: (d) cyclin D; (r) cyclin E.
of bars, during the hyperplastic growth period, there was
a reduction in the abundance of all three CKIs associated
with cdk2/cyclin E complexes. Again, this was consistent
with cyclin E kinase activation and a hyperplastic growthtypical blots, while Figure 5B summarizes these studies.
As shown, at day 2, cyclin D kinase activity was increased response. However, by day 5, there was a return toward
baseline values in the amount of p27 and p57 associated(68%), as was E kinase activity (130%), consistent with
the increase in BrdU incorporation at this time point with the complexes, which continued at day 10. By day
10, there was also an increase in the amount of p21and with an initial hyperplastic growth period. However,
at days 5 and 10, while cyclin D kinase activity was still associated with the complexes, which did not quite reach
statistical significance (P 5 0.063). However, when com-increased (66% at day 5 and 38% at day 10), cyclin E
kinase activity was inhibited (260% at day 5 and 224% pared with day 2, the increase in the p57:cdk2 ratio was
statistically different at both days 5 and 10, and theat day 10) compared with vehicle-treated animals. This
was consistent with the return of BrdU incorporation to p21:cdk2 ratio was statistically different at day 10. Thus,
retaining CKIs within a formed complex likely contrib-baseline levels and the end of the hyperplastic growth
period. utes to the inhibition of kinase activity. Taken together
with the study showing that complex abundance was alsoAn increase in cyclin D kinase at a time when cyclin
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Fig. 6. cdk2 abundance in cyclin E immuno-
precipitates. Using isolated proximal tubule
lysate, following immunoprecipitation with
cyclin E antibodies, immunoblotting using
anti-cdk2 antibodies was done to determine
the abundance of cdk2 in the immunoprecipi-
tates. Data are reported as a percentage of
control (vehicle-treated animals; N 5 5 to 7
per group per time point). *P , 0.05 vs. con-
trol (vehicle-treated animals); #P , 0.05 vs.
complex abundance at day 2.
Figure 8, TGF-b RII abundance was significantly de-
creased at day 2, but returned to baseline levels by day
5. In contrast, TGF-b RI protein abundance was un-
changed at days 2 and 5, but was significantly increased
by day 10. Taken together, TGF-b signaling was likely
decreased at day 2 (because of decreased RII expression)
and increased at days 5 and 10 (because of return of RII
expression and increased RI receptor expression).
Since the receptor expression pattern suggested that
TGF-b signaling was enhanced coincident with the
switch from a hyperplastic to hypertrophic growth re-
sponse, the next study examined regulation of Smad
protein abundance in isolated proximal tubules. As
shown in Figure 9, while there was a small effect on
Smad 2/3 protein abundance at day 2 and no effect atFig. 7. CKI:cdk2 ratio in cyclin E immunoprecipitates. Immunoblot-
ting was performed on cyclin E immunoprecipitates using anti-CKI day 5, there was a significant increase at day 10, sug-
and anti-cdk2 antibodies. The ratio of CKI:cdk2 is plotted on the y gesting up-regulation of TGF-b signaling.axis (N 5 5 to 7 per CKI per group per time point). Symbols are: (j)
Activation of the TGF-b signaling pathway results inp27:cdk2; (h) p57:cdk2; ( ) p21:cdk2. *P , 0.05 vs. control (vehicle-
treated animals); #P , 0.05 vs. CDI:cdk2 ratio at day 2. increased association of either Smad 2 or Smad 3 with
Smad 4, the Smad member common to multiple signaling
pathways. The complex then translocates to the nucleus
to effect transcriptional regulation. To examine Smaddecreased, these studies provide two mechanisms that
2/4 and Smad 3/4 complex abundances, Smad 4 was im-could contribute to the reduction in cyclin E kinase activ-
munoprecipitated from an isolated proximal tubule ly-ity between day 2 and days 5 and 10.
sate, and the abundance of coprecipitated Smad 2 and
TGF-b receptor abundance and signaling during 3 assayed by Western blotting. The results are presented
diabetes-induced renal hyperplasia and hypertrophy in Figure 10. There was a similar increase in Smad 2/4
complex abundance at all three time points, which be-Several studies have implicated TGF-b in mediating
came more consistent (day 2, increased in 3 of 8 sample;the renal growth associated with diabetes mellitus [re-
day 5, increased in 5 of 8 samples; day 10, increased inviewed in 17, 20], and we found in the in vitro cell cycle-
6 of 8 samples) and was statistically significant at day 10.dependent hypertrophy model that TGF-b could convert
In contrast, there was minimal regulation of Smad 3/4a mitogen-induced hyperplastic growth response to a
complex abundance at any time point. Taken togetherhypertrophic growth response [9, 10]. To determine
with the TGF-b receptor studies and studies showingwhether up-regulation of the TGF-b signaling system
that TGF-b mRNA and protein abundances were in-might be associated with the switch from a hyperplastic
creased as early as three-days post-STZ in cortical inter-to hypertrophic growth period in diabetes-induced renal
stitium and tubules [19], it is likely that TGF-b plays agrowth, TGF-b receptor protein abundance was mea-
sured on isolated proximal tubule lysates. As shown in role in mediating the inhibition of cyclin E kinase activity
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temporal relationship between these two growth patterns
in the proximal tubule in STZ-induced diabetes mellitus
and the mechanism responsible for the hypertrophic
growth.
Figure 11 is a schematic diagram of our working model
for proximal tubule growth in diabetes mellitus based
on the studies presented previously in this article. The
initial growth response is one of hyperplasia, marked by
entrance and progression through the cell cycle. Thus,
there is activation of both of the G1 kinases, cyclin D
and cyclin E, that is associated with an increase in DNA
synthesis (BrdU incorporation). By day 5, cyclin E kinase
activity is inhibited, while cyclin D kinase remains active.
The reduction in cyclin E kinase activity arrests cell cycle
progression into S phase, as demonstrated by a return
of the rate of DNA synthesis to baseline levels. This
combination of events leads to a switch from a hyperplas-
tic to a hypertrophic growth pattern.
The pattern of kinase activity during the hypertrophic
growth phase, that is, activation of cyclin D and inhibi-
tion of cyclin E, is consistent with the cell cycle-depen-
dent mechanism of hypertrophy that was characterized
in cultured renal epithelial cells [10–13]. In the in vitro
studies, it was shown that the conversion from a hyper-
plastic to a hypertrophic growth pattern is associated
with continued activation of cyclin D kinase, but inhibi-
tion of cyclin E kinase, identical to the kinase profile in
diabetes mellitus at the switch point [10]. Also similar
Fig. 8. TGF-b receptor protein abundance. Western blotting was per-
to the in vitro studies are the mechanisms associatedformed on isolated proximal tubule lysate using the appropriate anti-
TGF-b receptor antibody. Receptor abundance is reported as a per- with cyclin E kinase inhibition during the development
centage of control (vehicle-treated animals, N 5 4 to 6 per study per of hypertrophy [10]. These include both a decrease in the
group per time point). Symbols are: (j) TGF-b receptor I; ( ) TGF-b
abundance of cdk2/cyclin E complexes and an increase inreceptor II. *P , 0.05 vs. control (vehicle-treated animals). (A) Repre-
sentative blots. (B) Summary of all experiments. the abundance of CKIs associated with cdk2/cyclin E
complexes that do form. In both cultured renal epithelial
cells and isolated proximal tubules harvested from dia-
betic rats, there is a robust increase in complex formation
at days 5 and 10, and thus, in the switch from a hyperplas- during hyperplasia, which is inhibited by 63% in the in
tic to hypertrophic growth phase. vitro studies and .90% in the in vivo studies during the
development of hypertrophy.
In both the in vitro and in vivo hypertrophy models,DISCUSSION
CKIs also appear to play a role in the switch between a
Diabetic nephropathy is the leading cause of end-stage hyperplastic and hypertrophic growth pattern, although
renal disease (ESRD) in the United States, accounting the specific CKIs involved may be different. In the in
for 30 to 50% of all new patients entering the ESRD vitro studies, p57, but neither p27 or p21, appears to play
program each year [1]. The disease is marked by an a role, whereas in the diabetic hypertrophy model, all
increase in kidney size that is the consequence of both three CKIs likely contribute to the inhibition of cyclin
increased extracellular matrix accumulation and neph- E kinase activity. A larger contribution by the CKIs to
ron growth. The nephron growth involves primarily the the inhibition of kinase activity might explain why cyclin
glomerulus and proximal tubules. In both in vivo and in E kinase activity is close to baseline levels during the
vitro studies of mesangial cell growth in diabetes melli- development of hypertrophy in cultured cells, but less
tus, the data strongly suggest that there is no hyperplasia than baseline, or control (sham-treated animals) in the
present, but that mesangial cells do hypertrophy [25]. diabetic hypertrophy model.
Cortical studies suggest that both hyperplasia and hyper- In recent studies, particularly those involving glomeru-
trophy contribute to the proximal tubule growth in dia- lar mesangial cells, there is increasing evidence that CKIs
play a role in diabetes- or glucose-induced mesangialbetes mellitus [2–7]. The present studies examined the
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Fig. 9. Smad 2/3 protein abundance. Western
blotting was performed on isolated proximal
tubule lysate using an anti-Smad 2/3 antibody.
Protein abundance is reported as a percentage
of control (vehicle-treated animals, N 5 5 to
6 per group per time point). *P , 0.05 vs.
control (vehicle-treated animals).
to hypertrophy [9, 11–13]. TGF-b has also been impli-
cated in diabetes-induced renal growth [17, 19, 20, 28–
30]. Using in situ hybridization and immunohistochemis-
try, TGF-b mRNA abundance and protein expression
are increased in tubulointerstitial cells as early as three
days after STZ administration, which would be consis-
tent with TGF-b playing a role in the switch between
the hyperplastic and hypertrophic growth phases [19].
Thus, in the diabetic rats, studies were done to determine
whether enhanced TGF-b signaling is associated with the
conversion from a hyperplastic to hypertrophic growth
period. As presented, there is regulation of TGF-b recep-
tor expression, Smad 2/3 protein abundance, and Smad
2/4 complex abundance in isolated proximal tubules.
Taken together, these results clearly suggest that TGF-b
Fig. 10. Smad 2/4 (j) and 3/4 ( ) complex abundances. Following signaling may be involved in the inhibition of cyclin E
immunoprecipitation with an anti-Smad 4 antibody, Western blotting
kinase activity and the switch from the hyperplastic towas performed with either an anti-Smad 2 or anti-Smad 3-specific
antibody. Complex abundance is presented as a percentage of control hypertrophic growth phases. As the mechanisms associ-
(vehicle-treated animals, N 5 8 per group). ated with the inhibition of cyclin E kinase activity during
the development of hypertrophy are similar in the epi-
dermal growth factor 1 TGF-b and diabetes hypertro-
phy models, it is likely that TGF-b plays a role in the ingrowth in in vivo or in vitro studies, respectively. p21
vivo setting.expression increases with increased media glucose con-
In summary, the present studies clearly demonstratecentrations, which is consistent with inhibition of cyclin
that diabetes-induced renal growth in the STZ modelE kinase activity [25]. A role for p27 is less definitive, as
involves an initial hyperplastic growth period, followedone study showed no effect of glucose on p27 expression,
by a hypertrophic growth period. By comparison to thewhile another demonstrated increased expression, which
hypertrophy models characterized in in vitro studieswhen blocked with a p27 antisense oligonucleotide pre-
done on renal epithelial cells, the development of diabe-vented the glucose-induced hypertrophy [25, 26]. In in
tes-induced hypertrophy is mediated by the cell cycle-vivo studies in diabetic mice, there is again controversy,
dependent mechanism. This mechanism requires thatbut in some studies, there is suggestive evidence that
cells destined to hypertrophy enter the G1 phase, butboth p21 and p27 may play a role in the develop-
then experience an arrest of cell cycle progression inment of mesangial cell hypertrophy in diabetes mellitus
late G1, halting the initiation of DNA synthesis. The[25, 27].
switch between the hyperplastic and hypertrophicIn the in vitro studies on cultured renal epithelial cells,
growth phases in diabetes demonstrates these require-TGF-b was the growth regulatory agent that was able
to convert epidermal growth factor-induced hyperplasia ments, as cyclin D kinase activity is increased during
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Fig. 11. Model for renal growth in diabetes
mellitus.
autoradiographic studies of 3H-thymidine uptake in diabetic andboth growth phases (indicating that the cells are in G1), uninephrectomized rats. Diabetologia 25:280–287, 1983
but progression into S phase and the initiation of DNA 8. Franch HA, Preisig PA: NH4Cl-induced hypertrophy is mediated
by weak base effects and is independent of cell cycle processes.synthesis is present in the hyperplastic, but not hypertro-
Am J Physiol 270:C932–C938, 1996phic growth phase. As depicted in Figure 11, it is the
9. Franch HA, Shay JW, Alpern RJ, Preisig PA: Involvement of
differential activation of cyclin D and E kinases that pRB family in TGFb-dependent epithelial cell hypertrophy. J Cell
Biol 129:245–254, 1995mediates the development of cell cycle-dependent hyper-
10. Liu B, Preisig PA: TGFb-mediated hypertrophy in rat renal epi-trophy [10–12]. The present studies also suggest that
thelial cells involves inhibiting pRB phosphorylation by preventing
TGF-b plays a role in defining the hypertrophic growth activation of cdk2/cyclin E kinase. Am J Physiol 277:F186–F194,
1999period in diabetes-induced renal growth, making it in-
11. Preisig PA: Renal hypertrophy and hyperplasia, in The Kidney:creasingly likely that TGF-b plays a role in diabetic ne-
Physiology and Pathophysiology, edited by Selden DW, Giebisch
phropathy. G, Philadelphia: Lippincott, Williams & Wilkins (in press)
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